Table 1.
Demographics and clinical data table.
| Characteristics | CON |
BPD |
SCZ |
SIB |
|---|---|---|---|---|
| (n = 17) | (n = 17) | (n = 16) | (n = 12) | |
| Mean age (SD) | 35.6 (8.1) | 26.1 (3.2) | 35.8 (8.5) | 31.3 (8.6) |
| Gender (%) | ||||
| Female | 58.8 | 82.4 | 31.3 | 66.7 |
| Male | 41.2 | 17.6 | 68.7 | 33.3 |
| Race (%) | ||||
| Black | 64.7 | 5.9 | 50.0 | 33.3 |
| White | 35.3 | 94.1 | 50.0 | 66.7 |
| History of use disorder (%)a | ||||
| Nicotine | 29.4 | 41.2 | 68.8 | 33.3 |
| Alcohol | 5.9 | 35.3 | 31.3 | 16.7 |
| Cannabis | 5.9 | 23.5 | 31.3 | 8.3 |
| Stimulant | – | 5.9 | 6.3 | – |
| Opioid | – | – | 6.3 | – |
| Cocaine | 5.9 | – | 6.3 | – |
| Hallucinogen | – | – | 6.3 | – |
| Psychotropic medication (%) | ||||
| Typical neuroleptic | – | – | 12.5 | – |
| Atypical neuroleptic | – | 41.2 | 81.3 | – |
| SSRI | – | 29.4 | 18.8 | – |
| Other antidepressantsb | – | 23.5 | 18.8 | – |
| Mood stabilizer | – | 47.1 | 31.3 | – |
| Benzodiazepines | – | 11.8 | 12.5 | – |
| Stimulant | – | 17.6 | – | – |
| Anticholinergic | – | – | 18.8 | – |
| None | 100.0 | 29.4 | 12.5 | 100.0 |
| Symptom domainsc | ||||
| SAPS | 0.29 (0.8) | 2.59 (2.6) | 4.94 (3.5) | 0.50 (0.9) |
| Positive symptomsd | 0.06 (0.2) | 1.00 (1.4) | 3.75 (2.4) | 0.08 (0.3) |
| Disorganized symptomsd | 0.24 (0.7) | 1.59 (1.6) | 1.19 (1.7) | 0.42 (0.8) |
| SANSe | 2.29 (2.8) | 2.59 (3.5) | 7.94 (3.2) | 2.92 (2.7) |
a
Other than for nicotine use disorder, participants did not meet criteria for a use disorder in the last 6 months.
b
Refers to antidepressants other than selective serotonin reuptake inhibitors (SSRI).
c
Values given as means (SD).
d
Positive and Disorganized Symptoms were derived from the Structured Assessment of Positive Symptoms (SAPS). Maximum possible score on the SAPS is 16; and either positive or disorganized symptoms is 8.
e
Maximum possible score on the Structured Assessment of Negative Symptoms (SANS) is 20.